HWM
SABSW icon

HB Wealth Management’s SAB Biotherapeutics Warrant SABSW Stock Holding History

HB Wealth Management’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,000
Closed -$2.09K – 1277
2025
Q1 		$2.09K Buy
60,000
+9,999
+20% +$559 ﹤0.01% 1220
2024
Q4 		$3.87K Sell
50,001
-259,999
-84% -$15.7K ﹤0.01% 1074
2024
Q3 		$11.2K Buy
+310,000
New +$11.6K ﹤0.01% 975

Other funds holding SABSW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

HB Wealth Management's SABSW Position: Q2 2025 in Review

HB Wealth Management sold out of SAB Biotherapeutics Warrant (SABSW) in Q2 2025, closing a stake of 60,000 shares — an estimated $2.09K sold.

HB Wealth Management first reported a position in SABSW in Q3 2024 and held it in 3 quarters. The position peaked at $11.2K in Q3 2024. 6 funds tracked by Wall St. Rank hold SABSW as of Q2 2025.

  • HB Wealth Management reported no remaining SAB Biotherapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • HB Wealth Management sold 60,000 SAB Biotherapeutics Warrant shares in Q2 2025, an estimated $2.09K.
  • HB Wealth Management first reported a position in SAB Biotherapeutics Warrant in Q3 2024 and held it in 3 quarters.
  • HB Wealth Management's SAB Biotherapeutics Warrant position peaked at $11.2K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2025.

Based on HB Wealth Management's 13F filing for Q2 2025, filed 17 Jul 2025.